78 related articles for article (PubMed ID: 29137078)
1. Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study.
Lan CY; Wang Y; Xiong Y; Li JD; Shen JX; Li YF; Zheng M; Zhang YN; Feng YL; Liu Q; Huang HQ; Huang X
Lancet Oncol; 2018 Sep; 19(9):1239-1246. PubMed ID: 30082170
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
[TBL] [Abstract][Full Text] [Related]
3. Combat Against Gynecological Cancers with Blood Vessels as Entry Point: Anti-Angiogenic Drugs, Clinical Trials and Pre-Clinical Nano-Delivery Platforms.
Yang S; Fei W; Zhao Y; Wang F; Ye Y; Wang F
Int J Nanomedicine; 2023; 18():3035-3046. PubMed ID: 37312935
[TBL] [Abstract][Full Text] [Related]
4. Endostar Plus Apatinib Successfully Achieved Long Term Progression-Free Survival in Refractory Ovarian Cancer: A Case Report and Literature Review.
Xiao C; Xu F; Wang R; Liang Q; Shen K; Xu J; Liu L
Onco Targets Ther; 2021; 14():5363-5372. PubMed ID: 34880628
[TBL] [Abstract][Full Text] [Related]
5. Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression.
Wang Z; Huang Y; Long L; Zhou L; Huang Y; Gan L; Pu A; Li S; Xie R
J Ovarian Res; 2021 Jul; 14(1):91. PubMed ID: 34247630
[TBL] [Abstract][Full Text] [Related]
6. Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells.
Sun X; Li J; Li Y; Wang S; Li Q
Oxid Med Cell Longev; 2020; 2020():3145182. PubMed ID: 32509141
[TBL] [Abstract][Full Text] [Related]
7. Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells.
Chen L; Cheng X; Tu W; Qi Z; Li H; Liu F; Yang Y; Zhang Z; Wang Z
Cell Oncol (Dordr); 2019 Oct; 42(5):679-690. PubMed ID: 31325096
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy and immunotherapy for platinum-refractory advanced ovarian adenosquamous carcinoma: a case report.
Li A; Sun S; Song T; Li X; Cheng W; Yao R; Zhang D; Cai Z; Zhang J; Zhai D; Yu C
Onco Targets Ther; 2018; 11():3705-3711. PubMed ID: 29983579
[TBL] [Abstract][Full Text] [Related]
9. Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report.
Sun H; Xiao M; Liu S; Shi R
Medicine (Baltimore); 2018 Jul; 97(27):e11036. PubMed ID: 29979376
[TBL] [Abstract][Full Text] [Related]
10. Apatinib, a selective VEGFR2 inhibitor, improves the delivery of chemotherapeutic agents to tumors by normalizing tumor vessels in LoVo colon cancer xenograft mice.
Zhou K; Zhang JW; Wang QZ; Liu WY; Liu JL; Yao L; Cai MM; Ni SY; Cai QY; Wang GJ; Zhou F
Acta Pharmacol Sin; 2019 Apr; 40(4):556-562. PubMed ID: 29977004
[TBL] [Abstract][Full Text] [Related]
11. Efficacy And Safety Of Apatinib Treatment In Platinum-Resistant Recurrent Epithelial Ovarian Cancer: A Real World Study.
Zhang J; Li A; Jiang Q; Zheng F; Zhu H
Drug Des Devel Ther; 2019; 13():3913-3918. PubMed ID: 31814710
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of low-dose apatinib in ovarian cancer patients with platinum-resistance or platinum-refractoriness: A single-center retrospective study.
Chen W; Li Z; Zheng Z; Wu X
Cancer Med; 2020 Aug; 9(16):5899-5907. PubMed ID: 32627959
[TBL] [Abstract][Full Text] [Related]
13. Successful maintenance therapy with apatinib inplatinum-resistant advanced ovarian cancer and literature review.
Jin M; Cai J; Wang X; Zhang T; Zhao Y
Cancer Biol Ther; 2018; 19(12):1088-1092. PubMed ID: 30110192
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive treatment for multicentric giant cell tumors of the pelvis and spine using apatinib: A case report and literature review.
Li J; Zhou J; Liu Y; Sun X; Song W
J Cancer Res Ther; 2020 Sep; 16(5):1020-1026. PubMed ID: 33004743
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.
Zhang M; Tian Z; Sun Y
Medicine (Baltimore); 2017 Nov; 96(45):e8570. PubMed ID: 29137078
[TBL] [Abstract][Full Text] [Related]
16. Treatment of uterine high-grade endometrial stromal sarcoma with apatinib combined with chemotherapy: A case report.
Zhang Y; Chen C; Ren M; Cong X; Li Z; Yang L
Medicine (Baltimore); 2019 Mar; 98(13):e15050. PubMed ID: 30921232
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]